Cd4 +cd25 + regulatory t cells from MRL/lpr mice were functionally more active in vitro but did not prevent spontaneous as well as adriamycin-induced nephropathy in vivo

Rheumatology (United Kingdom)

Volumn 51, Issue 8, 2012, Pages 1357-1367

  Kim, Hyung Ran ^a   Kie, Jeong Hae ^b   Lim, Woosung ^a   Moon, Byung In ^a   Kim, Seung Cheol ^a   Seoh, Ju Young ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b National Health Insurance Corporation   (South Korea)

Author keywords

Adriamycin nephropathy; Lupus; MRL lpr mouse; Regulatory T cells; Suppressive activity

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; DOXORUBICIN; GLYCOPROTEIN P 15095;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; DENDRITIC CELL; DISEASE SEVERITY; DRUG INDUCED DISEASE; IN VITRO STUDY; IN VIVO STUDY; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY INJURY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; WILD TYPE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DOXORUBICIN; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED MRL LPR; NEPHRITIS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY;

EID: 84865188246     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes058     Document Type: Article

References (45)

1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
2. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167:1137-40.
3. Piccirillo CA, Shevach EM. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 2004;16: 81-8.
4. Lim HW, Hillsamer P, Banham AH, Kim CH. Cutting edge: direct suppression of B cells by CD4+CD25+ regulatory T cells. J Immunol 2005;175:4180-3.
5. Ralainirina N, Poli A, Michel T et al. Control of NK cell functions by CD4+CD25+ regulatory T cells. J Leukoc Biol 2007;81:144-53.
6. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. Cd4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 2002;17:167-78.
7. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004;4:665-74.
8. Annunziato F, Cosmi L, Liotta F et al. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J Exp Med 2002;196:379-87.
9. Turka LA, Walsh PT. IL-2 signaling and CD4+ CD25+ Foxp3+ regulatory T cells. Front Biosci 2008;13:1440-6.
10. Levings MK, Sangregorio R, Roncarolo MG. Human CD25(+)CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001;193:1295-302.
11. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000;164:183-90.
12. de la Rosa M, Rutz S, Dorninger H, Scheffold A. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 2004;34:2480-8.
13. Ono M, Yaguchi H, Ohkura N et al. Foxp3 controls regulatory T-cell function by interacting with aml1/runx1. Nature 2007;446:685-9.
14. Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982;69:1388-92.
15. Linker-Israeli M, Bakke AC, Quismorio FP Jr, Horwitz DA. Correction of interleukin-2 production in patients with systemic lupus erythematosus by removal of spontaneously activated suppressor cells. J Clin Invest 1985;75: 762-8.
16. Crispin JC, Alcocer-Varela J. Interleukin-2 and systemic lupus erythematosus-fifteen years later. Lupus 1998;7: 214-22.
17. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003;21:273-6.
18. Mellor-Pita S, Citores MJ, Castejon R et al. Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann Rheum Dis 2006;65:553-4.
19. Wu HY, Staines NA. A deficiency of CD4+CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen. Lupus 2004;13:192-200.
20. Abe J, Ueha S, Suzuki J et al. Increased foxp3(+) CD4(+) regulatory T cells with intact suppressive activity but altered cellular localization in murine lupus. Am J Pathol 2008;173:1682-92.
21. Bonelli M, von Dalwigk K, Savitskaya A, Smolen JS, Scheinecker C. Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis. Ann Rheum Dis 2008;67:664-71.
22. Bonelli M, Smolen JS, Scheinecker C. Treg and lupus. Ann Rheum Dis 2010;69(Suppl. 1):i65-6.
23. Long SA, Cerosaletti K, Bollyky PL et al. Defects in IL-2r signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010;59:407-15.
24. Parietti V, Monneaux F, Decossas M, Muller S. Function of CD4+,CD25+ Treg cells in mrl/lpr mice is compromised by intrinsic defects in antigen-presenting cells and effector T cells. Arthritis Rheum 2008;58:1751-61.
25. Yang CH, Tian L, Ling GS et al. Immunological mechanisms and clinical implications of regulatory T cell deficiency in a systemic autoimmune disorder: roles of IL-2 versus IL-15. Eur J Immunol 2008;38:1664-76.
26. Lyssuk EY, Torgashina AV, Soloviev SK, Nassonov EL, Bykovskaia SN. Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol 2007; 601:113-9.
27. Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178:2579-88.
28. Bonelli M, Savitskaya A, von Dalwigk K et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 2008;20:861-8.
29. Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, Alcocer-Varela J. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 2008;17:289-94.
30. Zhang B, Zhang X, Tang FL et al. Clinical significance of increased CD4+CD25-foxp3+ T cells in patients with new-onset systemic lupus erythematosus. Ann Rheum Dis 2008;67:1037-40.
31. Jung YJ, Seoh JY. Feedback loop of immune regulation by CD4+CD25+ Treg. Immunobiology 2009;214:291-302.
32. Jang MH, Jung YJ, Kim HR, Moon BI, Seoh JY. Immune homeostasis maintained by Tregs. In: Hayashi RS, ed. Regulatory T Cells. New York: Nova Science Publishers, 2011:201-23.
33. Yasuda K, Park HC, Ratliff B et al. Adriamycin nephropathy: a failure of endothelial progenitor cell-induced repair. Am J Pathol 2010;176:1685-95.
34. Wang YM, Zhang GY, Wang Y et al. Foxp3-transduced polyclonal regulatory T cells protect against chronic renal injury from adriamycin. J Am Soc Nephrol 2006;17: 697-706.
35. Mahajan D, Wang Y, Qin X et al. Cd4+CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J Am Soc Nephrol 2006;17: 2731-41.
36. Godfrey VL, Wilkinson JE, Russell LB. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol 1991;138:1379-87.
37. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6.
38. Ryffel B, Car BD, Gunn H et al. Interleukin-6 exacerbates glomerulonephritis in (NZB X NZW)F1 mice. Am J Pathol 1994;144:927-37.
39. Cash H, Relle M, Menke J et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in mrl-faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol 2010;37: 60-70.
40. Herber D, Brown TP, Liang S et al. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21r.Fc reduces disease progression. J Immunol 2007; 178:3822-30.
41. Rangan GK, Wang Y, Tay YC, Harris DC. Inhibition of nuclear factor-kappab activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 1999; 56:118-34.
42. Wang Y, Wang YP, Tay YC, Harris DC. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 2000;58: 1797-804.
43. Bertani T, Poggi A, Pozzoni R et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest 1982;46:16-23.
44. Milner LS, Wei SH, Houser MT. Amelioration of glomerular injury in doxorubicin hydrochloride nephrosis by dimethylthiourea. J Lab Clin Med 1991;118:427-34.
45. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22: 531-62.